Browsing: Drug Discovery

Artificial intelligence is transforming cancer care, accelerating drug discovery, and ushering in a new era of precision medicine with innovations like digital twins and nanorobots.

Artificial intelligence is rapidly transforming the field of drug discovery, with companies like Lila Sciences and Recursion Pharmaceuticals leading the way. These companies are leveraging AI scaling laws and building platforms that can accelerate the identification of new treatments and reshape scientific exploration.

Cresset integrates artificial intelligence to enhance productivity, reduce costs, and empower researchers in drug discovery.

Ben Taylor, CFO of Recursion Pharmaceuticals, discusses the rise of AI in biopharma, the importance of commitment in partnerships, and the challenges of data usage.

Artificial intelligence (AI) is poised to revolutionize drug development, offering solutions to the challenges of time and cost. This article explores the potential of AI in drug discovery, along with the data standardization, and data sharing within the pharmaceutical industry.

Dimension, a venture firm specializing in the intersection of life science and technology, has announced a $500 million fund, Dimension II, building on its initial $350 million fund.

Dimension, a biotech venture firm, has secured a $500 million fund to invest in companies at the intersection of life science and technology, focusing on tech-powered therapeutics and drug discovery tools.

Explore the potential of AI in revolutionizing drug discovery, its challenges, and the future of AI-human collaboration in the pharmaceutical industry.